Sumatriptan Succinate 100 mg Tablets Under Fasting Conditions
Condition: Healthy
Intervention: Sumatriptan Succinate; Imitrex®
Intervention description: 100 mg Tablets; 100 mg Tablet
Intervention MeSH terms: Sumatriptan
Phase: Phase 1
Study type: Interventional
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: None (Open Label)
Enrollment: 28.0
Sex: All
Minimum age: 18 Years
Maximum age: 40 Years
Healthy volunteers: Accepts Healthy Volunteers
Keywords: Bioequivalence; Healthy Subjects

Summary:

      The objective of this study is to compare the rate and extent of absorption of sumatriptan
      from a test formulation of Sumatriptan Succinate 100 mg Tablets versus the reference Imitrex®
      100 mg Tablets under fasting conditions.
    

Eligibility criteria:

        Inclusion Criteria

          -  Non-smoking (i.e. non-smoker or non-tobacco user for at least 90 days prior to
             pre-study medical screening) male or female within an age range of 18-40 years.

          -  Body Mass Index (BMI = weight/height2) greater than 19 kg/m2 and less than 26 kg/m2.

          -  Normal findings in the physical examination, vital signs (blood pressure between
             100-140/60-90 mmHg, heart rate between 50-80 beats/min) and 12-lead ECG.

          -  Negative for drugs of abuse, nicotine, alcohol, hepatitis B-surface antigen, hepatitis
             C and HIV, and for female subjects, pregnancy (serum β-CG).

          -  No clinical laboratory values outside of the acceptable range as defined by BCR,
             unless the Principal Investigator decides they are not clinically significant.

          -  Female subjects who are surgically sterile for at least six months or post-menopausal
             for at least one year, or who will avoid pregnancy prior to the study, during the
             study and up until one month after the end of the study.

        Exclusion Criteria

          -  Known history of hypersensitivity to sumatriptan (e.g. Imitrex®, Imigran®) and/or
             related drugs such as almotriptan, naratriptan, rizatriptan and zolmitriptan

          -  Known history or presence of cardiac, pulmonary, gastrointestinal, endocrine,
             musculoskeletal, neurological, hematological, liver or kidney disease, unless judged
             not clinically significant by the Principal Investigator or medical designate.

          -  Known history or presence of food allergies, or any condition known to interfere with
             the absorption, distribution, metabolism, or excretion of drugs.

          -  Any clinically significant illness during the last four weeks prior to entry into this
             study.

          -  Presence of any significant physical or organ abnormality.

          -  Any subject with a history of drug abuse.

          -  Any history or evidence of psychiatric or psychological disease (including depression)
             unless deemed not clinically significant by the Principal Investigator, or medical
             designate.

          -  Use of any prescription medication within 14 days preceding entry into this study.

          -  Use of any monoamine oxidase (MAO) inhibitor drugs such as phenelzine or
             tranylcypromine within 30 days preceding entry into this study.

          -  Use of over the counter (OTC) medication within seven days preceding entry into this
             study (except for spermicidal/barrier contraceptive products).

          -  Female subjects: use of oral contraceptives or contraceptive implants (such as
             Norplant®) within 30 days prior to drug administration or a depot injection of
             progestogen drug (e.g. Depo-Provera®) within one year prior to drug administration.

          -  Female subjects: presence of pregnancy or lactation.

          -  Any subject who has had blood drawn within 56 days preceding this study, taken during
             the conduct of any clinical study at a facility other than BCR, or within the lockout
             period specified by a previous study conducted at BCR.

          -  Participation in a clinical trial with an investigational drug within 30 days
             preceding this study.

          -  Any subject who has donated blood within 56 days preceding this study.

          -  Any subject who has participated as a plasma donor in a plasmapheresis program within
             seven days preceding this study.

          -  Significant or recent history of asthma (after 12 years of age).

          -  Any subject with a recent (less than one year) history of alcohol abuse.

          -  Known history of frequent headaches or migraines.

          -  Any subject with a parental or sibling history of heart attack or stroke that occurred
             under the age of 40 years.

          -  Intolerance to venipuncture.